[Imatinib--a breakthrough in the treatment of gastrointestinal stromal tumors (GIST)].
Gastrointestinal stromal tumours (GISTs) are rare gastro-intestinal, mesenchymal tumours characterized by the expression of a receptor with tyrosine kinase activity called c-kit. A new drug, Imatinib, is a potent inhibitor of a subgroup of the tyrosine kinase family comprising BCR-ABL, platelet-derived growth factor, and c-kit. Imatinib represents the first systemic treatment with a clinical effect on patients with metastatic or unresectable GISTs, which are known to be resistant to chemo and radiotherapy. In the first phase I and II studies confirmed partial responses were seen in 53% and 59% of the patients respectively.
Larsen
Jeanett Borregaard
JB
H:S Rigshospitalet, Finsencentret, Onkologisk Klinik. borregaard@dk2net.dk
D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001549:Benzamides; D005260:Female; D005770:Gastrointestinal Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D000068877:Imatinib Mesylate; D008297:Male; D010879:Piperazines / Q000008:administration & dosage*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D019009:Proto-Oncogene Proteins c-kit / Q000187:drug effects; D011743:Pyrimidines / Q000008:administration & dosage*; D020794:Receptor Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D017154:Stromal Cells / Q000473:pathology; D014057:Tomography, X-Ray Computed
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases; D019009:Proto-Oncogene Proteins c-kit; D020794:Receptor Protein-Tyrosine Kinases